execut continu impress innov
remain key growth prospect
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
valuat growth profit
methodolog valu compani
target larg potenti market opportun
nation heart blood lung institut estim
million american suffer sleep apnoea accord
fewer million diagnos
treat sleep apnoea year expand pool
diagnos treat sleep apnoea patient compani
target disord much gain
strategi involv increas awar disord
among physician gener popul compani
also make test sleep apnoea simpler home
test devic expand compani reach
patient unwil treat sleep lab
importantli aim introduc new devic
make patient comfort compliant
treatment provid compani stream
recur revenu
oan age popul coupl acceler obes
trend drive signific growth
steadi rate innov differenti
advantag histor support premium
omount evid clinic relev sleep
condit --
hypertens diabet -- increas demand
medic
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop manufactur distribut medic devic --
airflow gener mask -- treat breath disord also market
ventil product sleep apnoea remain compani primari
focu reach truli global distribut capabl
countri wholli own independ firm
increas proport manufactur capac singapor
still australia compani found
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
bilevel devic
entri
support
remain one key leader sleep apnoea
treatment admir innov capabl
expect compani deliv solid return long run
look forward see develop next
focus develop medic devic treat
sleep apnoea respiratori problem
educ caregiv therapi option firm
product portfolio consist airflow gener nasal
mask pillow introduc airflow need
prop open patient respiratori pathway sleep
tool help patient breath easier avoid
complic associ sleep apnoea includ
exhaust hypertens gener half
sale half sale
throughout europ japan
second mover sleep apnoea devic
initi forc play catch-up differenti
technic superior devic still aim maintain
technic edg serv well far patient
difficult time adjust sleep disrupt
advanc featur lead greater patient
comfort complianc turn lead brand loyalti
patient return sleep lab home
mask pillow -- highli profit recur revenu
stream help endear custom base
market free sampl past new product launch
continu impress innov
success combat price eros prevent
declin return capit
think prove abil develop new
sleep apnoea treatment expect
futur consid develop capabl
larg potenti patient pool remain
undiagnos untreat sleep apnoea market
look posit continu grow fast
clip fill gap exist therapeut option
valuat growth profit jan
fair valu estim stand usd per
share cost equiti use valuat line
cost equiti use valu global
medic devic compani st jude
next four year expect key demograph
trend especi age obes increas
penetr potenti patient pool greater
awar conveni test option drive
compound annual sale growth firm assum
competit environ five-year period
result limit scale economi firm increas
dollar/australian dollar exchang rate use
cost equiti discount assumpt
face tough competit though particularli
pioneer industri possess admir market
distribut capabl addit product
synonym sleep apnoea treatment
face difficult challeng tri educ
physician product set competitor also
shown willing compet price blanket
compani reach patient expect
educ home test initi
firm profit expand faster base forecast
either better oper effici stronger
dollar/australian dollar translat consid
rais fair valu estim usd per share
scenario assum sale increas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
sleep apnoea
effort rais clinic profil sleep-disord
breath increas awar sleep apnoea
particular despit sign increas competit mask
low-tech end flow gener believ
integr product suit creat applic
switch cost clinician patient key aspect
latest product offer built-in wireless
connect togeth on-line data informat
manag tool clinician bode well patient
support despit serve-hf trial setback clinic
evid date link sleep-disord breath host
medic disord beyond cardiolog repres futur
commerci opportun
treatment efficaci
view moat trend stabl
philip electron formerli respiron effect
duopoli domin market sleep apnoea
devic decad absenc potenti
disruptor horizon see chang
time soon proven abil innov
market healthcar stakehold think firm
remain leader market forese futur
expect momentum new product develop
maintain given on-going research develop
spend revenu
compound annual basi next five year
effect tax rate remain low near
demand product deceler result
competit threat margin contract
either oper ineffici weaker
dollar consid lower fair valu estim
usd per share scenario assum
sale increas compound annual basi
next five year
assign narrow moat rate base
intang asset switch cost given strong track
record innov product introduct coupl
solid patent posit dug narrow econom
moat around busi develop
market capabl sleep apnoea devic new
product launch core sleep apnoea busi
grow portfolio respiratori product focus copd
neuromuscular diseas cardio-respiratori condit
underpin posit stanc compani strong
competit posit market educ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pursu larg under-penetrated sleep-
disord breath market growth continu
strong trajectori patient incorpor
non-invasive treatment sleep
owith focu shift toward complianc rather
low-cost system thrive given
histori introduc innov product
oa signific boost at-hom sleep apnoea test
could open market patient balk
costli uncomfort test sleep lab
abil sell product depend larg
willing third parti pay treatment
lower reimburs rate product
would hurt revenu margin potenti
research
develop unabl introduc new product
marketplac success sale margin
ocompetit sampl hurt growth recent
year practic return attract
sleep apnoea devic market could diminish
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
nearli usd million cash cash equival
june compar usd million
total debt remain excel financi health
given abil gener signific free cash flow
expect posit strengthen futur year
like medical-devic firm must innov
face signific price pressur compani may
abl stay head innov class futur
year would creat open competitor
compani also face foreign exchang risk substanti
develop manufactur oper remain
australia firm found
sale dispers throughout rest
world account half sale
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
strong free cash flow gener intern
fund growth mani year issu fresh equiti
employ littl debt return invest capit
consist well cost capit
upward trend recent year major
growth follow three major contributor effect
invest research develop maintain
technolog invest clinic trial demonstr
medic benefit treat condit
distribut expertis reach
commend manag avers debt net cash
level somewhat excess opinion given limit
past question manag
zero-dividend polici prefer intermitt
repurchas stock manag credit
done price gener prove value-accret
pleas firm initi dividend
acquisit strategi buy rel small firm
complementari technolog
properti seen manag risk materi
amount capit acquisit found
value-destruct
current ceo mick farrel posit sinc
son founder peter farrel
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
republican look close solv tax reform
long expect senat republican leadership
recent pass tax reform lite plan
potenti bring last chang
corpor tax system may modifi certain tax
reform-rel assumpt incorpor model
dont anticip materi chang fair valu
estim econom moat rate firm
earn exposur due variou offset factor
believ tax reform like occur
product hous senat reconcili effort
committe direct align previou
assumpt remind assum follow
model corpor tax rate begin
elect firm either fulli expens
manufactur capit expenditur made deduct
net interest expens deem repatri tax
oversea earn held cash elimin
assess shape belief variou faction
republican parti would ultim compromis
sake legisl win unlik healthcar tax reform
close held goal parti constitu
decad howev bill passag senat
fulli guarante becom law congression
leader reconcil hous senat
version tax bill goe joint confer
committe next week addit senat bill
pass slim vote still confound
factor bear monitor upcom senat
elect alabama robert mueller investig
said think bill passag senat
significantli rais likelihood core reform
eventu find way onto presid trump desk
bottom line tax reform final inning
part senat tax reform bill either
posit neg corpor taxat
consequ valuat anticip
posit propos reduct corpor tax rate
senat hous bill cut tax
rate aggress assumpt
variou member congress eas back
area tax reform bill neg valuat
includ time corpor tax cut deem
repatri rate limit net oper loss usag
treatment depreci treatment net interest
expens senat hous bill
contempl corpor tax rate senat lower
rate would take effect assumpt
line hous plan would
corpor tax rate lower assum
deem repatri tax rate oversea earn
held cash senat bill rate
cash cash-equival profit well
senat bill allow expens short-liv capit
invest equip machineri five year
cap net interest expens unlik hous bill
howev senat version phase
expens capit invest provis percentag
point per year thereaft rather call
immedi sunset effect gener
senat plan hous plan less benefici
previou assumpt would allow
firm elect full expens manufactur capit
expenditur perpetu give net interest
expens deduct senat implement phase-
mean curtail intens lobbi effort
would occur immedi cliff
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
senat version bill restor corpor
altern minimum tax conspicu absent
hous version bill moreov senat version
bill begin
carryforward would limit taxabl incom
hous bill initi set
net oper
senat gop legisl victori accompani
news former nation secur advisor lieuten
gener michael flynn agre co-oper
special counsel robert mueller mueller current
investig trump administr offici alleg
collus member russian govern
reiter view dont anticip derail
tax reform effort congress even alleg affect
highest level govern
inform regard underpin
department view tax reform pleas see april
note lift brambl fve aud base
report anoth solid quarter buoy
mask sale rais fve usd oct
narrow-moat report excel first quarter
result net profit tax million group
revenu million prior
correspond period slightli ahead
expect buoy strong perform mask
 strong uptak flow gener europ
latter year year due favor
reimburs rate franc second largest
retail market connect across product platform
focu manag commentari
compani unveil enhanc brightre offer
combin data analyt autom resuppli alert
home care provid patient flow oper
remain strong million pcp quarterli
dividend per share declar repres
pay-out ratio maintain confid
sustain dividend medium term
increas fair valu estim per share
follow increas compound-annual-growth-rate
assumpt mask equat aud
per cdi base aud/usd exchang rate
regard stock fairli valu current level
solid demand airfit airfit led
impress increas sale year year although
uplift mask sale due
fulfil order hamper manufactur suppli
constraint previou quarter overal market
mask grow around annual remain
comfort sale growth target fiscal
given launch airtouch full-fac mask last
quarter see brightre offer optim
replenish opportun downstream custom
 devic sale also remain robust increas
pcp compar market mid-single-digit growth
think reflect market share gain
competitor new busi clinician attract
cloud enabl suit flow gener remain
posit prospect devic given evid increas
patient complianc maintain target growth rate
fiscal
success latest gener devic follow
launch solut platform
howev skew product mix away mask
past three year mask fiscal repres
group revenu compar fiscal
weigh gross margin
declin fiscal around
first-quart
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
respect increas patient complianc improv
outcom chang reimburs franc
telemonitor case point believ trend
toward digit connect care add meaning
time drive adopt resm solut
ecosystem includ aircurv
devic platform well airview myair softwar
stronger australian dollar legal cost
otherwis strong result maintain fve
bring group revenu fiscal usd million
constant-curr basi year year
line expect nonetheless
strengthen australian dollar coupl
ramping-up litigation-rel legal cost fiscal
drove sell gener administr sg
expens higher percentag revenu result
lower-than-expect net incom usd million
compar consensu forecast usd million
forecast usd million said guidanc given
manag indic legal cost eas fiscal
lead moder sg provid aud/
usd exchang rate remain stabl maintain usd
per share fair valu estim equat
aud per cdi base australian dollar/u dollar
exchang rate manag also guid
increas effect tax rate owe mix
compar averag recent year final
dividend usd quarter bring total full-
year dividend usd repres pay-out ratio
compar forecast assumpt
remain posit medium- long-term prospect
compani given launch airtouch mask
airmini cpap devic period think
complement market-lead suit cloud-
five-year compound-annual-growth-rate mask devic sale growth
global gross margin consolid level
stabilis around
notabl increas recognit econom
benefit cloud-connect monitor clinician
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end june
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end june
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
